North America Cervical Cancer Screening, Diagnostics, And Pre-cancerous Dysplasia Lesion Treatment Market Size & Outlook

The cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market in North America is expected to reach a projected revenue of US$ 6,600.7 million by 2035. A compound annual growth rate of 6.1% is expected of North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market from 2025 to 2035.
Revenue, 2024 (US$M)
$3,473.2
Forecast, 2035 (US$M)
$6,600.7
CAGR, 2025 - 2035
6.1%
Report Coverage
North America

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market, 2018-2035 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market highlights

  • The North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market generated a revenue of USD 3,473.2 million in 2024.
  • The market is expected to grow at a CAGR of 6.1% from 2025 to 2035.
  • In terms of segment, cervical cancer screening was the largest revenue generating type in 2024.
  • Cervical Cancer Screening is the most lucrative type segment registering the fastest growth during the forecast period.
  • Country-wise, Canada is expected to register the highest CAGR from 2025 to 2035.


North America data book summary

Market revenue in 2024USD 3,473.2 million
Market revenue in 2035USD 6,600.7 million
Growth rate6.1% (CAGR from 2025 to 2035)
Largest segmentCervical cancer screening
Fastest growing segmentCervical Cancer Screening
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2035
Quantitative unitsRevenue in USD million
Market segmentationCervical Cancer Screening, Cervical Cancer Diagnostics, Pre-cancerous Lesion Treatment


Other key industry trends

  • In terms of revenue, North America region accounted for 41.2% of the global cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2035.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 3,288.6 million by 2035.

Cervical cancer screening was the largest segment with a revenue share of 51.36% in 2024. Horizon Databook has segmented the North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market based on cervical cancer screening, cervical cancer diagnostics, pre-cancerous lesion treatment covering the revenue growth of each sub-segment from 2018 to 2035.


North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market Growing significantly. North America has made remarkable progress in reducing cervical cancer incidence and mortality over the past several decades, primarily through extensive cervical cancer screening programs. 

These initiatives rely heavily on Pap smears (cytology) and, increasingly, human papillomavirus (HPV) testing. However, despite high overall screening rates in many regions, disparities persist in screening participation and follow-up care, particularly among underserved populations. 

To address these gaps, healthcare systems across North America are adopting innovative solutions. Recent FDA approvals for HPV self-collection tests, such as the cobas HPV and BD Onclarity HPV assays, present a promising alternative for women who may avoid traditional pelvic exams due to discomfort, cultural sensitivities, or past trauma.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Companies

Name Profile # Employees HQ Website
MedGyn Products View profile 51-100 Addison, Illinois, United States, North America https://www.medgyn.com
Utah Medical Products Inc View profile 190 7043 South 300 West, Midvale, UT, United States, 84047 http://www.utahmed.com
CooperSurgical View profile 501-1000 Trumbull, Connecticut, United States, North America http://www.coopersurgical.com
Hologic Inc View profile 6990 250 Campus Drive, Marlborough, MA, United States, 01752 http://www.hologic.com
Qiagen NV View profile 5900 Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL https://www.qiagen.com
Becton Dickinson & Co View profile 73000 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880 https://www.bd.com
Abbott Laboratories View profile 114000 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 https://www.abbottinvestor.com
Roche Holding AG ADR View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com

North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market size, by country, 2018-2035 (US$M)

North America Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook Share, 2024 & 2035 (US$M)

North America cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market size, by country, 2018-2035 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online